Jay S. Duker - Jul 10, 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Jul 10, 2024
Transactions value $
-$70,033
Form type
4
Date filed
7/12/2024, 05:04 PM
Previous filing
Feb 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +16.7K +56.65% $0.00 46.1K Jul 10, 2024 Direct
transaction EYPT Common Stock Tax liability -$70K -8.06K -17.49% $8.69 38K Jul 10, 2024 Direct F1
holding EYPT Common Stock 22.5K Jul 10, 2024 By Family Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -16.7K -33.33% $0.00 33.3K Jul 10, 2024 Common Stock 16.7K $0.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
F2 These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3 The restricted stock units vests in three ratable annual installments beginning July 10, 2024.